2-Methoxymethyl-salvinorin B is a Potent Kappa Opioid Receptor Agonist with Longer Lasting Action in Vivo Than Salvinorin A

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 2007 Dec 20

PMID 18089845

Citations 40

Authors

Yulin Wang

Yong Chen

Wei Xu

David Y W Lee

Zhongze Ma

Scott M Rawls

Alan Cowan

Lee-Yuan Liu-Chen

Affiliations

Soon will be listed here.

Abstract

Salvinorin (Sal) A is a naturally occurring, selective kappa opioid receptor (KOPR) agonist with a short duration of action in vivo. Pharmacological properties of a C(2) derivative, 2-methoxymethyl (MOM)-Sal B, were characterized. MOM-Sal B bound to KOPR with high selectivity and displayed approximately 3-fold higher affinity than U50,488H [(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methanesulfonate] and Sal A. It acted as a full agonist at KOPR in guanosine 5'-O-(3-[(35)S]thio)triphosphate binding and was approximately 5- and approximately 7-fold more potent than U50,488H and Sal A, respectively. In Chinese hamster ovary cells stably expressing KOPR, all three kappa agonists internalized or down-regulated KOPR to similar extents, with MOM-Sal B being the most potent. In mice, MOM-Sal B (0.05-1 mg/kg s.c.) caused immediate and dose-dependent immobility lasting approximately 3 h, which was blocked by norbinaltorphimine. In contrast, ambulation in a Y-maze was increased when rats received MOM-Sal B (1-5 mg/kg s.c.). In addition, MOM-Sal B (0.5-5 mg/kg i.p.) produced antinociception (hot-plate test) and hypothermia in a dose-dependent manner in rats. MOM-Sal B was more potent than U50,488H in both tests and more efficacious than U50,488H in the hot-plate test. These latter two in vivo effects were blocked by norbinaltorphimine, indicating KOPR-mediated actions. Sal A at 10 mg/kg elicited neither antinociception nor hypothermia 30 min after administration to rats. In summary, MOM-Sal B is a potent and efficacious KOPR agonist with longer lasting in vivo effects than Sal A.

Citing Articles

Emerging Psychotropic Drug for the Treatment of Trigeminal Pain: Salvinorin A.

Quinonez-Bastidas G, Grijalva-Contreras L, Patino-Camacho S, Navarrete A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770461 PMC: 11728561. DOI: 10.3390/ph17121619.

Synthesis and Conformational Analysis of FR901464-Based RNA Splicing Modulators and Their Synergism in Drug-Resistant Cancers.

Beard J, Bressin R, Markaj P, Schmitz J, Koide K J Med Chem. 2023; 66(21):14497-14512.

PMID: 37870431 PMC: 10641826. DOI: 10.1021/acs.jmedchem.3c00733.

Kappa opioid receptor activation increases thermogenic energy expenditure which drives increased feeding.

Cone A, Wu K, Kravitz A, Norris A iScience. 2023; 26(7):107241.

PMID: 37485355 PMC: 10362357. DOI: 10.1016/j.isci.2023.107241.

The Kappa Opioid Receptor Agonist 16-Bromo Salvinorin A Has Anti-Cocaine Effects without Significant Effects on Locomotion, Food Reward, Learning and Memory, or Anxiety and Depressive-like Behaviors.

van de Wetering R, Ewald A, Welsh S, Kornberger L, Williamson S, McElroy B Molecules. 2023; 28(12).

PMID: 37375403 PMC: 10304272. DOI: 10.3390/molecules28124848.

Ligand and G-protein selectivity in the κ-opioid receptor.

Han J, Zhang J, Nazarova A, Bernhard S, Krumm B, Zhao L Nature. 2023; 617(7960):417-425.

PMID: 37138078 PMC: 10172140. DOI: 10.1038/s41586-023-06030-7.

References

Siebert D . Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol. 1994; 43(1):53-6. DOI: 10.1016/0378-8741(94)90116-3. View

Zhang Y, Butelman E, Schlussman S, Ho A, Kreek M . Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl). 2005; 179(3):551-8. DOI: 10.1007/s00213-004-2087-0. View

Fantegrossi W, Kugle K, Valdes 3rd L, Koreeda M, Woods J . Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol. 2005; 16(8):627-33. DOI: 10.1097/00008877-200512000-00005. View

Beguin C, Richards M, Wang Y, Chen Y, Liu-Chen L, Ma Z . Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). Bioorg Med Chem Lett. 2005; 15(11):2761-5. DOI: 10.1016/j.bmcl.2005.03.113. View

Butelman E, Mandau M, Tidgewell K, Prisinzano T, Yuferov V, Kreek M . Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther. 2006; 320(1):300-6. DOI: 10.1124/jpet.106.112417. View

Schmidt M, Schmidt M, Butelman E, Harding W, Tidgewell K, Murry D . Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse. 2005; 58(3):208-10. DOI: 10.1002/syn.20191. View

Roth B, Baner K, Westkaemper R, Siebert D, Rice K, Steinberg S . Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A. 2002; 99(18):11934-9. PMC: 129372. DOI: 10.1073/pnas.182234399. View

Inan S, Cowan A . Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav. 2006; 85(1):39-43. DOI: 10.1016/j.pbb.2006.07.004. View

Chavkin C, Sud S, Jin W, Stewart J, Zjawiony J, Siebert D . Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther. 2004; 308(3):1197-203. DOI: 10.1124/jpet.103.059394. View

10.

Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee D . Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther. 2004; 312(1):220-30. DOI: 10.1124/jpet.104.073668. View

11.

Li J, Luo L, Krupnick J, Benovic J, Liu-Chen L . U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation. J Biol Chem. 1999; 274(17):12087-94. DOI: 10.1074/jbc.274.17.12087. View

12.

Lee D, Karnati V, He M, Liu-Chen L, Kondaveti L, Ma Z . Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. Bioorg Med Chem Lett. 2005; 15(16):3744-7. DOI: 10.1016/j.bmcl.2005.05.048. View

13.

Lee D, Ma Z, Liu-Chen L, Wang Y, Chen Y, Carlezon Jr W . New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors. Bioorg Med Chem. 2005; 13(19):5635-9. DOI: 10.1016/j.bmc.2005.05.054. View

14.

McLAUGHLIN C, Tao Q, Abood M . Analysis of the antinociceptive actions of the kappa-opioid agonist enadoline (CI-977) in neonatal and adult rats: comparison to kappa-opioid receptor mRNA ontogeny. Drug Alcohol Depend. 1995; 38(3):261-9. DOI: 10.1016/0376-8716(95)01124-h. View

15.

Valdes 3rd L . Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J Psychoactive Drugs. 1994; 26(3):277-83. DOI: 10.1080/02791072.1994.10472441. View

16.

Schmidt M, Prisinzano T, Tidgewell K, Harding W, Butelman E, Kreek M . Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 818(2):221-5. DOI: 10.1016/j.jchromb.2004.12.041. View

17.

Munro T, Rizzacasa M, Roth B, Toth B, Yan F . Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem. 2005; 48(2):345-8. PMC: 2777653. DOI: 10.1021/jm049438q. View

18.

Li J, Zhang F, Jin X, Liu-Chen L . Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. J Pharmacol Exp Ther. 2003; 305(2):531-40. DOI: 10.1124/jpet.102.045559. View

19.

McCurdy C, Sufka K, Smith G, Warnick J, Nieto M . Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav. 2006; 83(1):109-13. DOI: 10.1016/j.pbb.2005.12.011. View

20.

Carlezon Jr W, Beguin C, Dinieri J, Baumann M, Richards M, Todtenkopf M . Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther. 2005; 316(1):440-7. DOI: 10.1124/jpet.105.092304. View